Table 2 Univariate and multivariate analyses of progression-free survival in patients with cervical cancer treated with combination immunotherapy.

From: Systemic immune-inflammatory index predict short-term outcome in recurrent/metastatic and locally advanced cervical cancer patients treated with PD-1 inhibitor

Variables

Univariable analysis

Multivariable analysis

HR (95%CI)

P

HR (95%CI)

P

Age (≤ 60 vs. >60)

0.701 (0.355–1.383)

0.306

  

Pathological type

Squamous carcinoma

1.889 (0.455–7.842)

0.381

  

Adenocarcinoma

    

FIGO Stage

IIB-IVA

1.976 (0.936–4.173)

0.074

  

Recurrent/metastatic

    

Treatment

ICIs & Chemoradiotherapy

0.686 (0.360–1.310)

0.254

  

ICIs & radiotherapy

    

ICIs & Chemotherapy

    

NLR(≤ 3.76 vs. >3.76)

3.139 (1.632–6.037)

0.001

0.521(0.138–1.968)

0.336

PLR(≤ 218.1 vs. >218.1)

3.804 (1.911–7.572)

< 0.001

2.419(0.747–7.838)

0.141

LMR(≤ 3.34 vs. >3.34)

0.604 (0.294–1.242)

0.17

  

SII(≤ 1147.7 vs. >1147.7)

4.671 (2.457–8.879)

< 0.001

3.539(1.256–9.976)

0.017

PNI(≤ 43.75 vs. >43.75)

0.379 (0.200-0.719)

0.003

0.575(0.285–1.157)

0.121

  1. ICIs, immunocheckpoint inhibitors; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio; SII, systemic immune-inflammation index; PNI, prognostic nutritional index.
Back to article page